You are here

Veklury

13 July 2020

The Australian Prescription Medicine Decision Summary provides a short overview of the TGA's evaluation process leading to the registration of a new prescription medicine on the Australian Register of Therapeutic Goods (ARTG).

More in-depth information about the evaluation will be available in the Australian Public Assessment Report (AusPAR) for a particular prescription medicine, which can be found on the AusPAR search page once published.

Australian prescription medicine decision summary

Summary of submission

Submission type
New chemical entity
Product name
Veklury
Active ingredients
Remdesivir
ATC codes
Not yet assigned
Decision
Approved for provisional registration
Date of decision
10 July 2020
Date of entry onto ARTG
10 July 2020
ARTG numbers
338419, 338420
Black Triangle Scheme
Yes. As a provisionally registered product, this medicine will remain in the Black Triangle Scheme for the duration of its provisional registration.
Sponsor
Gilead Sciences Pty Ltd
Sponsor address
Level 6, 417 St Kilda Road, Melbourne, Victoria 3004
Dose forms
Concentrated injection, powder for injection
Strength

Concentrated injection: 100 mg/20 mL

Powder for injection: 100 mg

Other ingredients

Concentrated injection: sulfobutyl betadex sodium, hydrochloric acid, sodium hydroxide, water for injection.

Powder for injection: sulfobutyl betadex sodium, hydrochloric acid, sodium hydroxide.

Containers
Vial
Pack sizes
One
Routes of administration
Intravenous infusion
Dosage

Use of Veklury is confined to healthcare facilities in which patients can be monitored closely. Veklury is for single use in one patient only.

The recommended dosage of Veklury in patients 12 years of age and older and weighing at least 40 kg is:

  • Day 1 - a single loading dose of Veklury 200 mg given by intravenous infusion
  • Day 2 onwards - 100 mg given once-daily by intravenous infusion

The total duration of treatment should be at least 5 days and not more than 10 days. For further information on dosage, refer to the Product Information.

Pregnancy category

B2

Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed.

Studies in animals are inadequate or may be lacking, but available data show no evidence of an increased occurrence of fetal damage.

The use of any medicine during pregnancy requires careful consideration of both risks and benefits by the treating health professional. This must not be used as the sole basis of decision making in the use of medicines during pregnancy. The TGA does not provide advice on the use of medicines in pregnancy for specific cases. More information is available from obstetric drug information services in your State or Territory.

What was approved?

Veklury (remdesivir) was provisionally approved for the following therapeutic use:

Veklury has provisional approval for the treatment of Coronavirus Disease 2019 (COVID-19) in adults and adolescents (aged 12 years and older weighing at least 40 kg) with pneumonia, requiring supplemental oxygen.
The decision to approve this medicine has been made based on limited data. More comprehensive evidence is required to be submitted.

The provisional registration period for the above medicine is two years starting on the day specified in the Australian Register of Therapeutic Goods (ARTG) certificate of registration.

What is this medicine and how does it work?

What was the decision based on?

What steps were involved in the decision process?

What post-market commitments will the sponsor undertake?

As a provisionally registered medicine, extensive post-market commitments are required of the sponsor. The following is a summary of the post-market commitments.

  • Veklury (remdesivir) is to be included in the Black Triangle Scheme. The Product Information (PI) and Consumer Medicines Information (CMI) for Veklury must include the black triangle symbol and mandatory accompanying text for the products entire period of provisional registration.
  • The Veklury European Union-risk management plan (EU-RMP; Version 1.0, dated 24 June 2020, data lock point 27 May 2020), with Australian specific Annex (version 0.1, dated 3 July 2020), included with submission PM-2020-01491-1-2, to be revised to the satisfaction of the TGA, and subsequent versions, as agreed with the TGA, will be implemented in Australia.

An obligatory component of risk management plans is routine pharmacovigilance. Routine pharmacovigilance includes the submission of periodic safety update reports (PSURs).

Reports are to be provided in line with the current published list of EU reference dates and frequency of submission of PSURs until the period covered by such reports is not less than three years from the date of the approval letter.

The reports are to at least meet the requirements for PSURs as described in the European Medicines Agency’s Guideline on Good Pharmacovigilance Practices (GVP) Module VII-periodic safety update report (Rev 1), Part VII.B Structures and processes. Note that submission of a PSUR does not constitute an application to vary the registration.

  • Additional to the submission of routine PSURs, the sponsor provides to the TGA expedited monthly remdesivir safety summary reports (including safety data for patients in Australia) for the first 6 months post registration, and thereafter at intervals specified by the TGA.
  • Confirmatory trial data (as identified in the sponsor’s plan to submit comprehensive clinical data on the safety and efficacy of the medicine before the end of the 6 years that would start on the day that registration would commence) must be provided.
    Specifically, the sponsor must provide the study reports for studies as specified in Part III.2. Additional Pharmacovigilance activities of the Veklury EU-RMP (Version 1.0, dated 24 June 2020, data lock point 27 May 2020).
    Clinical study reports (CSRs) for the following remdesivir studies/data should be submitted to the TGA, once available:
    • Study GS-US-540-5773 (final CSR expected in December 2020 for Part A).
    • Study GS-US-540-5774 (final CSR expected in December 2020 for Part A).
    • Study CO-US-540-5776 (ACTT-I) (final CSR expected in December 2020).
    • An analysis of all available safety data from clinical trials CO-US-540-5776, GS-US-5405773, GS-US-540-5774 and CO-US-540-5758 when completed, including case narratives, detailed information about adverse reaction and exposure data as well as an analysis of occurrence and aggravation of adverse events (AEs), serious adverse events (SAEs) and adverse drug reactions (ADRs) are associated with increasing exposure.
    • Remdesivir pregnancy safety reports (yearly submission of annual reports).
    • Phase I study in subjects with hepatic impairment (final CSR expected in November 2021).
    • Phase I study in subjects with severe renal impairment and subjects with end stage renal disease on dialysis (final CSR expected in September 2021).
  • The additional quality data requested should be provided to the TGA.
  • The additional nonclinical data requested should be provided to the TGA.

Further information

The latest information about medicines and medical devices as it relates to COVID-19 can be found at: Coronavirus (COVID-19): Information on medicines and medical devices.

The latest Product Information (PI) and Consumer Medicines Information (CMI) can be found at: ARTG search.

Australian Public Assessment Reports (AusPARs) can be found at: AusPAR search.

The latest news and updates regarding therapeutic goods regulation can be found at: TGA news room.